ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)

被引：2
|
作者：
Ibrahim, Nuhad
Kim, Sung-Bae
Lin, Nancy
Awada, Ahmad
Gil, Eva Ciruelos
Tonini, Giulia
Vallespir, Bartomeu Piza
Theall, Kathy Puvana
Hamilton, Erika
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-05-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-05-05
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Yardley, Denise A.
    Liggett, William
    Mainwaring, Mark
    Castrellon, Aurelio
    Blakely, Laura
    Hemphill, Brian
    Anz, Bertrand, III
    Young, Robyn R.
    Shastry, Mythili
    DeBusk, Laura M.
    Hainsworth, John D.
    Burris, Howard A., III
    CLINICAL BREAST CANCER, 2020, 20 (02) : 89 - 97
  • [32] A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
    Li, Allen
    Naik, Arpana
    Johnson, Nathalie
    Goodyear, Shaun
    Johnson, Brett
    Park, Byung
    Corless, Christopher
    Gray, Joe
    Mills, Gordon
    Mitri, Zahi
    CANCER RESEARCH, 2021, 81 (04)
  • [33] Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)
    Chae, Heejung
    Sim, Sung Hoon
    Kwon, Youngmi
    Lee, Eun-Gyeong
    Han, Jai Hong
    Jung, So-Youn
    Lee, Seeyoun
    Kang, Han-Sung
    Kim, Yeon-Joo
    Kim, Tae Hyun
    Lee, Keun Seok
    CANCERS, 2024, 16 (18)
  • [34] H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Hamilton, Erika P.
    Pluard, Timothy J.
    Wang, Judy S.
    Morikawa, Aki
    Johnston, Stephen R. D.
    Dees, Elizabeth Claire
    Vaklavas, Christos
    Armstrong, Anne C.
    Munster, Pamela N.
    Unni, Nisha
    Wright, Gail Lynn Shaw
    Kayali, Fadi
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [36] acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).
    Martin, Miguel
    Lim, Elgene
    Mac Gregor, Mariana Chavez
    Shivhare, Mahesh
    Ross, Graham
    Patre, Monika
    Roncoroni, Laura
    Louka, Maria
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
    Fasching, Peter A.
    Bardia, Aditya
    Quiroga, Vanesa
    Park, Yeon Hee
    Blancas, Isabel
    Alonso, Jose Luis
    Vasilyev, Alexander
    Adamchuk, Hryhoriy
    Salgado, Marcelo Ramos Tejo
    Yardley, Denise A.
    Spera, Gonzalo
    Xue, Cloris
    Ferreira, Erika
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Fernando, Tharu M.
    Moore, Heather M.
    Hurvitz, Sara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] H3B-6545+palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Johnston, Stephen R. D.
    Pluard, Timothy J.
    Wang, Judy S.
    Hamilton, Erika P.
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
    Bardia, Aditya
    Kaklamani, Virginia
    Wilks, Sharon
    Weise, Amy
    Richards, Donald
    Harb, Wael
    Osborne, Cynthia
    Wesolowski, Robert
    Karuturi, Meghan
    Conkling, Paul
    Bagley, Rebecca G.
    Wang, Yamei
    Conlan, Maureen G.
    Kabos, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (12) : 1360 - +
  • [40] The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients
    Reinert, Tomas
    do Rego, Fernanda Orpinelli
    Silva, Matheus Costa e
    Rodrigues, Amanda Muniz
    Koyama, Fernanda Christtanini
    Goncalves, Aline Coelho
    Pauletto, Maiane Maria
    de Carvalho Oliveira, Leandro Jonata
    de Resende, Cristiano Augusto Andrade
    Landeiro, Luciana Castro Garcia
    Barrios, Carlos Henrique
    Mano, Max Senna
    Dienstmann, Rodrigo
    FRONTIERS IN ONCOLOGY, 2024, 14
12345